You are here: Industry Insights > Sanofi

News List

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps pharmaphorum
February 27, 2019
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Sanofi, Regeneron lose patent dispute with Amgen over cholesterol drug pharmaceutical-technology
February 27, 2019
US District Court for the District of Delaware has upheld Amgen’s patent on cholesterol drug Repatha, rejecting a challenge filed by Sanofi and Regeneron.
Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal fiercepharma
February 24, 2019
Sanofi scooped up nanobody biotech Ablynx last year in a $4.5 billion deal—and now, the buyout may be starting to pay off. Cablivi, an Ablynx nanobody for a rare blood-clotting disorder, has snagged its FDA green light.
Sanofi, buoyed by Dupixent and rare disease drugs, expects a brighter 2019 fiercepharma
February 24, 2019
Sanofi’s growth momentum seems to have returned after years of diabetes-related decline. With a major contribution from Dupixent—plus some help from new blood disorder treatments added through recent acquisitions and a renewed focus on oncology—Sanofi is
PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60% fiercepharma
February 24, 2019
It’s not often that a tit-for-tat pricing battle goes public in biopharma—and that sort of fight is perhaps even more rare for prerebate list prices.
Sanofi's new chief digital officer joins wave of executives looking to leverage tech for treatments fiercepharma
February 24, 2019
It's another digital chief for Big Pharma, this time at Sanofi. The French drugmaker tapped chief medical officer Ameet Nathwani, M.D., as its first chief digital officer, combining the two roles inside the company just as it aims to join treatments and t
Insulin pricing lawsuit against Sanofi, Novo Nordisk and Eli Lilly moves forward fiercepharma
February 24, 2019
Insulin giants are facing unprecedented scrutiny for their pricing, thanks to a growing gap between their retail stickers and prices after behind-the-scenes discounts and rebates. And now they'll have to face class-action claims about those very practices
It's not a Brexit problem, Sanofi says of epilepsy drug shortages fiercepharma
February 24, 2019
Sanofi has restarted production at a plant where manufacturing had to be halted to fix pollution issues. The interruption created spot shortages of seizure drugs Epilim and Depakote in some markets, but Sanofi has assured patients it has nothing to do wit
Philippine officials pull Dengvaxia's marketing license, but Sanofi asks them to reconsider fiercepharma
February 24, 2019
Sanofi set off an uproar in the Philippines with its 2017 disclosure that dengue shot Dengvaxia can cause more serious infections in some cases. Now, after investigations and more, the country’s FDA has permanently revoked the vaccine’s marketing license.
Sanofi announces myeloma drug meets primary endpoint pharmaceutical-technology
February 19, 2019
French pharma giant Sanofi has unveiled that its multiple myeloma drug isatuximab has met its primary endpoint of prolonged progression-free survival in a Phase III trial.....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page